Skip to main content
Premium Trial:

Request an Annual Quote

Exact Sciences' Q3 Revenues Up; Loss Rises on Increased Expenses

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Exact Sciences today reported that its third-quarter revenues rose around 8 percent and its net loss more than tripled as the firm significantly upped its investment in R&D.

The Madison, Wis.-based molecular diagnostics firm brought in total revenues of $1.4 million for the three-month period ended Sept. 30, compared to $1.3 million for the third quarter of 2009. Nearly all of its revenues came from license fees.

Exact's net loss for the quarter was $3.4 million, or $.08 per share, compared to $1 million, or $.03 per share, for the third quarter of 2009.

The loss was driven by a sharp increase in R&D spending, which rose to $2.6 million from $837,000 year over year. The firm also increased its SG&A spending to $2.1 million from $1.5 million.

Exact finished the quarter with $34.8 million in cash, cash equivalents, and marketable securities.

"Exact Sciences' primary focus during the third quarter was the completion of our validation study, a major milestone in our efforts to bring to market an accurate, patient-friendly screening test that detects both pre-cancers and cancer," Exact President and CEO Kevin Conroy said in a statement.

The firm is developing a stool-based DNA colorectal cancer screening test. It is scheduled to present data from a validation study of the test tomorrow at the American Association for Cancer Research conference.

The Scan

Genetic Testing Approach Explores Origins of Blastocyst Aneuploidy

Investigators in AJHG distinguish between aneuploidy events related to meiotic missegregation in haploid cells and those involving post-zygotic mitotic errors and mosaicism.

Study Looks at Parent Uncertainties After Children's Severe Combined Immunodeficiency Diagnoses

A qualitative study in EJHG looks at personal, practical, scientific, and existential uncertainties in parents as their children go through SCID diagnoses, treatment, and post-treatment stages.

Antimicrobial Resistance Study Highlights Key Protein Domains

By screening diverse versions of an outer membrane porin protein in Vibrio cholerae, researchers in PLOS Genetics flagged protein domain regions influencing antimicrobial resistance.

Latent HIV Found in White Blood Cells of Individuals on Long-Term Treatments

Researchers in Nature Microbiology find HIV genetic material in monocyte white blood cells and in macrophages that differentiated from them in individuals on HIV-suppressive treatment.